Tenon Medical Q2 Revenue Jumps 127% to $1.3M, Gross Margin Hits 64%
TNON sits 31% above its 52-week low of $4.375 on light trading volume (0.3× avg).
Summary
Tenon Medical reported Q2 2026 revenue of $1.3 million, up 127% year-over-year, with gross margin improving to 64%. The company also announced FDA clearance for its updated Catamaran system and record July case volume, but faces a $5.2 million convertible note maturity in September.
Key Events · Earnings and Guidance · TNON
-
Q2 Revenue Up 127%
Revenue reached $1.3 million in Q2 2026, up from $0.6 million in Q2 2025, driven by higher surgical procedure volume and the SImmetry+ System.
-
Gross Margin Expands to 64%
Gross profit was $0.8 million, a 232% increase year-over-year, with gross margin improving 21 percentage points to 64% due to higher revenue and lower fixed costs.
-
FDA 510(k) Clearance
The updated Catamaran SI Joint Fusion System received FDA clearance, reclassifying certain instruments from disposable to reusable, expected to reduce per-procedure costs.
-
Record July Case Volume
July 2026 marked the highest monthly surgical case volume to date, following a 98% increase in physician and distributor training events in 1H 2026 versus 2H 2025.
Analysis · TNON · Industrial Applications And Services
Tenon Medical delivered its strongest second quarter yet, with revenue up 127% to $1.3 million and gross margin expanding to 64% from 43% a year ago. The company also received FDA 510(k) clearance for its updated Catamaran system and recorded record monthly case volume in July. However, cash remains tight at $1.7 million, and $5.2 million in convertible notes mature in September, keeping the going-concern risk front and center.
At the time of this filing, TNON was trading at $5.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3M. The 52-week trading range was $4.38 to $60.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.